Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant, non-breastfeeding females 18 years-of-age or older~* A diagnosis of CLL as defined by IWCLL 2008 criteria and currently on treatment with ibrutinib for at least 18 months with residual disease and without evidence of disease progression.~* No more than 4 prior lines of anti leukemia therapy (not including ibrutinib)~* Life expectancy of at least 9 months~* Karnofsky performance score 70~* Adequate baseline laboratory assessments~* Signed informed consent form~* Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1~* Subjects with reproductive capability must agree to practice adequate contraception methods.~Exclusion Criteria:~* Subjects experiencing toxicity with ibrutinib~* Prior treatment with any Hsp90 inhibitor.~* Major surgery or significant traumatic injury within 4 weeks of starting study treatment.~* Conventional chemotherapy or radiation within 4 weeks.~* The need for treatment with medications with clinically-relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422~* Screening ECG QTc interval 470 msec for females, 450 msec for males.~* At increased risk for developing prolonged QT interval unless corrected to within normal limits prior to first dose of SNX-5422~* Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.~* Gastrointestinal diseases or conditions that could affect drug absorption or could alter the assessment of safety~* History of documented adrenal dysfunction not due to malignancy.~* History of chronic liver disease.~* Active hepatitis A or B.~* Current alcohol dependence or drug abuse.~* Use of an investigational treatment (except for ibrutinib) from 30 days prior to the first dose~* Glaucoma, retinitis pigmentosa, macular degeneration, or any retinal changes detected by ophthalmological examination that are considered clinically important by examiner.~* Psychological or social reasons that would hinder or prevent compliance with the requirements of the protocol or compromise the informed consent process.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SNX-5422 plus ibrutinib (Type: EXPERIMENTAL): Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).